Treatment of metastatic malignant melanoma

Current Treatment Options in Oncology

Volumn 6, Issue 3, 2005, Pages 185-193

  Atallah, Ehab ^b   Flaherty, Lawrence ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; INTERFERON; INTERLEUKIN 2; ITRACONAZOLE; PACLITAXEL; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; VINBLASTINE;

ABDOMINAL DISTENSION; ADOPTIVE IMMUNOTHERAPY; ALOPECIA; ASCITES; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE RESECTION; BRAIN METASTASIS; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG METABOLISM; DYSPNEA; EAR DISEASE; EDEMA; ELECTROLYTE DISTURBANCE; EXPERIENCE; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART TAMPONADE; HUMAN; HYPOTENSION; INFECTION; KIDNEY FAILURE; LIMB PERFUSION; LIVER METASTASIS; LUNG CONGESTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOCYTOPENIA; MALAISE; MEDICAL DECISION MAKING; MELANOMA; META ANALYSIS; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; OLIGURIA; PATIENT SELECTION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; RADIOSURGERY; REVIEW; SIDE EFFECT; STEREOTAXIC SURGERY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 21744439869     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0002-5     Document Type: Review

References (31)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012.
3. Barth A, Wanek LA, Morton DL: Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995, 181:193-201.
4. Bajetta E, Del Vecchio M, Bernard-Marty C, et al.: Metastatic melanoma: chemotherapy. Semin Oncol 2002, 29:427-445.
5. Gogas H, Bafaloukos D, Bedikian AY: The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 2004, 14:415-420.
6. Bleehen NM, Newlands ES, Lee SM, et al.: Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995, 130:910-913.
7. Middleton MR, Grob JJ, Aaronson N, et al.: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients With advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158.
8. Al Sarraf M, Fletcher W, Oishi N, et al.: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 1982, 66:31-35.
9. Glover D, Glick JH, Weiler C, Fox K, Guerry D: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987, 5:574-578.
10. Glover D, Ibrahim J, Kirkwood J, et al.: Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003, 13:619-626.
11. Lattanzi SC, Tosteson T, Chertoff J, et al.: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995, 5:365-369.
12. Chapman PB, Einhorn LH, Meyers ML, et al.: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
13. Legha SS, Ring S, Papadopoulos N, et al.: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989, 64:2024-2029.
14. Buzaid A, Legha S, Winn R, et al.: Cisplatin (C) vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology program (CCOP) trial. Proc Am Soc Clin Oncol 1993, 12:389.
15. Hwu WJ, Krown SE, Menell JH, et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003, 21:3351-3356.
16. Eton O, Legha SS, Bedikian AY, et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045-2052.
17. Atkins MB, Lee S, Flaherty LE, et al.: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2, and IFN-α-2b versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003, 22:708.
18. Keilholz U, Punt CJ, Gore M, et al.: Dacarbazine, cisplatin and IFN-α-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 2003, 22:708.
19. Atkins MB, Lotze MT, Dutcher JP, et al.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
20. Legha SS: The role of IFN-α in the treatment of metastatic melanoma. Semin Oncol 1997, 24:24-31.
21. Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immuno 2001, 24:287-293.
22. Tarhini AA, Agarwala SS: Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004, 16:161-166.
23. Lavine SD, Petrovich Z, Cohen-Gadol AA, et al.: Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 1999, 44:59-64.
24. Brand CU, Ellwanger U, Stroebel W, et al.: Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997, 79:2345-2353.
25. Meyer T, Merkel S, Goehl J, Hohenberger W: Surgical therapy for distant metastases of malignant melanoma. Cancer 2000, 89:1983-1991.
26. Ollila DW, Hsueh EC, Stern SL, Morton DL: Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999, 71:209-213.
27. Alexander HR, Jr, Fraker DL, Bartlett DL: Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996, 12:416-428.
28. Thompson JF, Kam PC: Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004, 88:1-3.
29. Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14639-14645.
30. Flaherty KT, Brose M, Schuchter L, et al.: Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. Proceedings of ASCO annual meeting. New Orleans, LA; 2004.
31. Falkson CI, Ibrahim J, Kirkwood JM, et al.: Phase III trial of dacarbazine versus dacarbazine with interferon-α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon-α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:1743-1751.